Please use this identifier to cite or link to this item:
Title: Safety and immunogenicity of a 2009 influenza A (H1N1) vaccine in hemodialysis patients
Authors: Lertdumrongluk P.
Changsirikulchai S.
Limkunakul C.
Prachukthum P.
Punpiput P.
Buppanharun R.
Chotpitayasunondh C.
Keywords: influenza vaccine
virus antibody
2009 H1N1 influenza
antibody blood level
antibody response
antibody titer
controlled study
drug safety
hemagglutination inhibition
hemodialysis patient
high risk patient
injection site contusion
injection site erythema
injection site pain
injection site swelling
major clinical study
priority journal
prospective study
treatment outcome
virus immunity
Antibodies, Viral
Cohort Studies
Hemagglutination Inhibition Tests
Influenza A Virus, H1N1 Subtype
Influenza Vaccines
Influenza, Human
Middle Aged
Prospective Studies
Renal Dialysis
Time Factors
Treatment Outcome
Issue Date: 2012
Abstract: A worldwide vaccination campaign against the 2009 pandemic influenza A (H1N1) virus was launched among high-risk subjects, including hemodialysis patients. The long-term immunogenicity of an influenza vaccine has not been investigated in hemodialysis patients. This study aimed to (1) assess the long-term immunogenicity of a monovalent non-adjuvanted influenza A (H1N1) vaccine in hemodialysis patients and (2) determine the safety of this vaccine. We conducted a prospective cohort study of 44 hemodialysis patients and 149 healthy controls in 2010. All of the participants received a single dose of the monovalent non-adjuvanted 2009 influenza A (H1N1) vaccine. The level of antibodies was measured at baseline and at 4 and 24 weeks post-vaccination using a hemagglutination inhibition assay. The outcomes were the percentages of participants who achieved seroconversion and seroprotection (titer ≥1:40) 4 and 24 weeks after vaccination. At 4 weeks post-vaccination, seroconversion was observed in 17 (38.6%) of the hemodialysis patients and 94 (63.1%) of the controls (P= 0.056), and protective titers were obtained in 22 (50%) of the hemodialysis patients and 100 (67.1%) of the controls (P= 0.426). At 24 weeks post-vaccination, immunogenicity decreased in both the hemodialysis patients and the controls, but there were no significant differences between the hemodialysis patients and the controls in the seroconversion rate (27.3% versus 36.9%, P= 0.526) or the seroprotection rate (38.6% versus 48.3%, P= 0.996). No differences in adverse events were observed between the hemodialysis patients and the controls. In summary, the 2009 influenza A (H1N1) vaccine elicits a similar immune response in both hemodialysis patients and healthy controls, but immunity declines 24 weeks after vaccination in both groups. Hemodialysis patients should at least be vaccinated annually against the influenza virus. © 2011 Elsevier Ltd.
ISSN: 0264410X
Appears in Collections:Scopus 1983-2021

Files in This Item:
There are no files associated with this item.

Items in SWU repository are protected by copyright, with all rights reserved, unless otherwise indicated.